Close this search box.


$10 – $15 / Week

Magazine Menu :

Close this search box.

The Future of Pharmaceuticals: Pioneering Solutions for Antibiotic-Resistant Diseases 

In an era marked by the rising threat of antibiotic-resistant bacteria, the need for novel antimicrobial agents has never been more urgent. Acurx Pharmaceuticals

In an era marked by the rising threat of antibiotic-resistant bacteria, the need for novel antimicrobial agents has never been more urgent. Acurx Pharmaceuticals is developing innovative antibiotics for priority pathogens identified by global health organizations. Acurx Pharmaceuticals is leading in tackling infectious diseases by addressing medical needs and fighting antibiotic resistance.

Addressing Urgent Medical Needs


  Acurx Pharmaceuticals focuses on developing new antibiotics to fight priority bacterial infections recognized by WHO, CDC, and FDA. These priority pathogens resist antibiotics, creating public health threats and emphasizing the urgency for new treatments. At the core of Acurx Pharmaceuticals’ mission is its commitment to innovation and scientific excellence. The company focuses on finding unique antibiotics to target vulnerabilities in priority pathogens. Acurx Pharmaceuticals uses advanced tech and microbiology insights to develop safe antibiotics against resistance, offering new treatments for patients.

Clinical-Stage Advancements

   Acurx Pharmaceuticals has made significant progress in advancing its antibiotic candidates through clinical development. The company’s pipeline includes promising candidates that have shown efficacy and safety profiles in preclinical and early clinical studies. Acurx Pharmaceuticals aims to quickly bring innovative antibiotics to market by following guidelines, addressing medical needs, and improving outcomes. Beyond its focus on pharmaceutical innovation, Acurx Pharmaceuticals upholds principles of sustainability and corporate responsibility. The company prioritizes environmental stewardship and ethical business practices, integrating these values into operations and decision-making in the pharmaceutical industry.

Collaborative Partnerships

     Acurx Pharmaceuticals recognizes the importance of collaboration in accelerating antibiotic development and addressing antibiotic resistance. The company partners with top academic, research, and government institutions to access varied expertise and resources for developing new antibiotics. By fostering partnerships and sharing knowledge, Acurx Pharmaceuticals aims to maximize its impact and contribute to global efforts to combat infectious diseases. Acurx understands the importance of collaboration and partnership in driving innovation and accelerating the development of new antibiotics. Through strategic collaborations with leading academic institutions, research organizations, and industry partners, Acurx leverages collective expertise and resources to advance its pipeline and expand its impact on global health.

Leadership Journey

David Luci , co-founder, President, and CEO of a prominent pharmaceutical company, has a distinguished career in pharmaceutical companies, legal practice, and accounting. He has made significant contributions to the development and commercialization of life-saving medications. Luci’s tenure at Dipexium Pharmaceuticals, a company focused on antibiotic drug development, led to a successful merger valued at $69 million.

Experience in Pharmaceutical Industry 

  Luci’s extensive experience in the pharmaceutical sector spans various leadership positions. He served as a member of the board of directors and President of MacroChem, contributing to the company’s strategic direction and operational success. Additionally, his role as Executive Vice President, Chief Financial Officer, General Counsel, and Corporate Secretary of Bioenvision, Inc. underscores his multifaceted expertise in finance, law, and corporate governance. Luci holds a Bachelor of Science in Business Administration from Bucknell University, with a concentration in Accounting. He furthered his education at Albany Law School of Union University, where he earned his Juris Doctor degree and served as Managing Editor of the Journal of Science & Technology. As a certified public accountant and member of the New York State Bar Association, Luci brings a unique blend of financial acumen and legal expertise to his leadership roles.

Professional Credentials

  David Luci’s accounting and corporate law roles were crucial in developing his skills and expertise in the pharmaceutical industry. During his time at Ernst & Whinney LLP, Luci gained invaluable insights into financial management and regulatory compliance, laying a solid foundation for his future endeavors. His experience as a CPA gave him valuable insight into financial reporting, auditing, and compliance crucial to pharmaceutical operations. At Paul Hastings LLP, Luci grew his skills in M&A, corporate finance, and private equity transactions. His healthcare sector focus exposed him to complex deal structures and unique considerations in the pharmaceutical industry.

Strategic Vision and Execution

   David Luci, at Acurx Pharmaceuticals, focuses on innovation, value for shareholders, and global health impact in fighting antibiotic-resistant infections. Mr. Luci and his team aim to advance infectious disease management globally by excelling in science, compliance, and corporate responsibility. David Luci’s leadership at Acurx Pharmaceuticals exemplifies the transformative power of visionary leadership in the pharmaceutical industry. Mr. Luci’s strategic vision, innovation commitment, and patient care passion drive healthcare innovation and positive change. His background in accounting and law offers a well-rounded view crucial to overseeing a pharmaceutical company like Acurx Pharmaceuticals.

Share your love

Subscribe To Our Weekly Newsletter

Get notified for our latest news
We’ll never spam your inbox
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore